Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight

DelveInsight forecasts positive growth in the vasomotor-symptoms treatment market across the US, EU4, UK and Japan through 2036, supported by aging demographics, greater diagnosis and demand for non-hormonal therapies. US VMS prevalence is estimated at about 46% in early menopausal transition and 60%-80% during menopause/postmenopause, underscoring a substantial addressable population. Pipeline momentum includes positive Phase II ABCL635 data, Phase III STARLIGHT 2 success for Astellas' fezolinetant in Japan, and positive Phase IIa results for Noema's cendifensine, though adoption remains contingent on efficacy, safety, regulatory approvals and differentiation.

Analysis

This is primarily a pipeline-validation signal rather than an investable market-size revision: the addressable population is large, but commercialization will be governed by persistence, payer step-edits, and safety monitoring rather than diagnosis rates. For Astellas, the emerging oral non-hormonal category raises the probability of a competitive, rather than monopoly, market; incumbency, prescriber familiarity and formulary access should matter more over the next 12-24 months than incremental mechanism claims from early-stage entrants.

ABCL is the only liquid direct read-through, but its antibody approach faces a demanding product-profile hurdle against oral therapies: a subcutaneous treatment must demonstrate materially better efficacy, durability, or safety to offset administration friction. Positive mid-stage data may improve platform credibility and partnership optionality in the next 1-3 months, yet it does not establish peak-sales economics absent dose durability, discontinuation rates, manufacturing cost, and payer willingness to reimburse an injectable for a chronic quality-of-life indication.

BAYN is better positioned than PFE to capture a differentiated niche if its non-hormonal asset gains traction among women receiving endocrine therapy after breast cancer, where hormone avoidance is not merely preference-driven. The contrarian view is that category expansion can be value-destructive for later entrants: generic hormone therapy and low-cost OTC alternatives create a high bar, while the leading oral NK3 pathway has already established the clinical and reimbursement benchmark. This press-release forecast supplies no independently verifiable market-size, pricing, or share assumptions and is not itself a catalyst.

Near term, monitor ABCL's full Phase 2 dataset for absolute reduction versus placebo, liver/safety profile, injection frequency, and durability; these determine whether the asset merits strategic value beyond a platform headline. Over 6-18 months, formulary positioning and real-world discontinuation for marketed non-hormonal agents will be the key read-through for every pipeline program; broad prior-authorization requirements would compress the entire category's peak-sales estimates.

Key Decisions for Investors

• Maintain ABCL as a small catalyst watch, not a directional core long, pending full Phase 2 disclosure. Consider initiating only if durability and tolerability support quarterly-or-longer dosing and the stock does not re-rate materially on topline enthusiasm; risk is that an injectable profile proves commercially inferior to oral competitors.
• Prefer BAYN over PFE for a 6-18 month niche-exposure basket: endocrine-therapy-associated VMS has a clearer clinical segmentation and lower hormone substitution risk. Falsify on weak Canadian uptake, restricted reimbursement, or evidence that prescribers default to established oral alternatives.
• Avoid treating VTGN as a VMS thematic long before controlled efficacy data and financing requirements are clear. Its program remains too early for category-growth forecasts to support valuation; monitor cash runway and trial design as the gating variables.
• Do not establish a TXMD or VERU position on this news. Neither has a sufficiently direct, current public-market earnings lever from the outlined pipeline, and the article's inclusion of legacy menopause names should not be mistaken for a revenue catalyst.
• Set an industry alert around payer coverage and discontinuation data for marketed NK3 therapies over the next 1-3 quarters. Broad access plus sustained adherence would raise ABCL strategic optionality; safety-driven restrictions or high abandonment would argue for lower peak-sales assumptions across the non-hormonal cohort.